Jurgen Brockmoller

Summary

Country: Germany

Publications

  1. ncbi request reprint The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment
    Jurgen Brockmoller
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 72:438-52. 2002
  2. ncbi request reprint Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Berlin, Germany
    Clin Pharmacokinet 43:267-78. 2004
  3. ncbi request reprint Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Pharmacogenetics 12:101-9. 2002
  4. ncbi request reprint Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
    Elena A Gaikovitch
    Institute of Clinical Pharmacology, University Clinic Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Eur J Clin Pharmacol 59:303-12. 2003
  5. ncbi request reprint Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Psychopharmacol 23:459-66. 2003
  6. ncbi request reprint Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
    Pierre Benoit Tremblay
    Institute of Clinical Pharmacology and Department of Hematology and Oncology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Oncol 21:2147-55. 2003
  7. ncbi request reprint Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 72:62-75. 2002
  8. ncbi request reprint Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Laboratory of Clinical Neurobiology, Charite University Medicine, Berlin, Germany
    Pharmacogenet Genomics 15:579-87. 2005
  9. ncbi request reprint Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:186-94. 2003
  10. ncbi request reprint Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics
    Isabella Gashaw
    Institute of Clinical Pharmacology, Charite University Medical Center, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:448-57. 2003

Detail Information

Publications47

  1. ncbi request reprint The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment
    Jurgen Brockmoller
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 72:438-52. 2002
    ..The impact of the polymorphism on haloperidol pharmacokinetics, adverse events, and efficacy was prospectively evaluated under naturalistic conditions in 172 unselected psychiatric inpatients with acute psychotic symptoms...
  2. ncbi request reprint Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Berlin, Germany
    Clin Pharmacokinet 43:267-78. 2004
    ..According to in vitro data, about 70% of nateglinide intrinsic clearance may be mediated by cytochrome P450 (CYP) 2C9 and a smaller fraction by CYP3A4 and CYP2D6...
  3. ncbi request reprint Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Pharmacogenetics 12:101-9. 2002
    ..The pronounced differences in pharmacokinetics due to the amino acid variants did not significantly affect plasma insulin and glucose concentrations in healthy volunteers...
  4. ncbi request reprint Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
    Elena A Gaikovitch
    Institute of Clinical Pharmacology, University Clinic Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Eur J Clin Pharmacol 59:303-12. 2003
    ..However, little is known of the frequency distribution of the major allelic variants in the Russian population...
  5. ncbi request reprint Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Psychopharmacol 23:459-66. 2003
    ..This indicates that both CYP2C enzymes contribute to the demethylation of desmethyltrimipramine and CYP2D6 to further metabolism...
  6. ncbi request reprint Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
    Pierre Benoit Tremblay
    Institute of Clinical Pharmacology and Department of Hematology and Oncology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Oncol 21:2147-55. 2003
    ..The 5-HT3B subunit seems to be most important for its functionality. We hypothesized that patients with genetic variations in the 5-HT3B receptor gene might respond differently to antiemetic treatment...
  7. ncbi request reprint Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 72:62-75. 2002
    ..In humans, there are 2 variants of CYP2C9 with a high population frequency. We studied their impact on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2...
  8. ncbi request reprint Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Laboratory of Clinical Neurobiology, Charite University Medicine, Berlin, Germany
    Pharmacogenet Genomics 15:579-87. 2005
    ..We studied the effect of the CYP2D6 duplication genotype on doxepin pharmacokinetics and platelet serotonin uptake and concentrations...
  9. ncbi request reprint Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:186-94. 2003
    ..The consequences of CYP2C9 genetic polymorphisms on fluvastatin pharmacokinetics and on its efficacy have not been investigated in humans thus far...
  10. ncbi request reprint Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics
    Isabella Gashaw
    Institute of Clinical Pharmacology, Charite University Medical Center, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:448-57. 2003
    ..We also wanted to identify whether genetically determined high CYP3A5 expression is associated with increased alprazolam clearance...
  11. ncbi request reprint Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes
    Rolf Kaiser
    Institute of Clinical Pharmacology and Department of Hematology and Oncology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Oncol 20:2805-11. 2002
    ....
  12. ncbi request reprint Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists
    Rolf Kaiser
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, D 10098 Berlin, Germany
    Pharmacogenetics 14:271-8. 2004
    ..Two subunits, the 5-HT3A and 5-HT3B are expressed in anatomical structures known to be involved in the mechanism of acute cytostatic drug induced emesis...
  13. ncbi request reprint Pharmacogenetics-based new therapeutic concepts
    Ivar Roots
    Institut fur Klinische Pharmakologie, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Humboldt Universitat zu Berlin, Berlin, Germany
    Drug Metab Rev 36:617-38. 2004
    ..g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market...
  14. ncbi request reprint Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 76:302-12. 2004
    ..We compared metoprolol pharmacokinetics and effects in UMs with extensive metabolizers (EMs) and with poor metabolizers (PM) as an additional reference group...
  15. pmc Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University, Berlin, Germany
    Br J Clin Pharmacol 55:51-61. 2003
    ..As a surrogate marker of diclofenac activity, the ex vivo formation of prostaglandin E2 and thromboxane B2, which reflects COX-2 and COX-1 activity, was measured...
  16. ncbi request reprint Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Germany
    Pharmacogenetics 14:19-26. 2004
    ..However, regarding phenprocoumon hydroxylation CYP2C9 genotypes had only marginal effects on S- and R-phenprocoumon total clearance in healthy volunteers...
  17. ncbi request reprint Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Pharmacogenetics 13:473-80. 2003
    ..It remains to be shown whether this is associated with greater efficacy or with an increased incidence and severity of adverse events...
  18. ncbi request reprint Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Humboldt University Berlin, Germany
    J Clin Psychopharmacol 24:647-52. 2004
    ..We hypothesized that ultrarapid metabolizers (defined as carriers of the CYP2D6 gene duplication plus another functional allele) have a risk for therapeutic failure due to too low tissue concentrations...
  19. ncbi request reprint Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Pharmacogenetics 13:619-26. 2003
    ..The role of this allele should also be studied in other CYP2B6 substrates, including cyclophosphamide, halothane, mianserin, promethazine and propofol...
  20. ncbi request reprint Validity of PCR with emphasis on variable number of tandem repeat analysis
    Rolf Kaiser
    Institute of Clinical Pharmacology, Universitatsklinikum Charite, Humboldt Universitat Berlin, D 10098, Berlin, Germany
    Clin Biochem 35:49-56. 2002
    ..Variable number of tandem repeat polymorphisms (VNTR) are frequently analyzed by PCR in genetic, epidemiologic and forensic studies. We wanted to explore the validity of these PCR analyses...
  21. ncbi request reprint Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum )
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Psychopharmacol 22:46-54. 2002
    ..John's wort extract may explain this pharmacokinetic interaction. Physicians should be aware of this interaction when treating patients with amitriptyline...
  22. ncbi request reprint Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Eur J Clin Pharmacol 58:581-5. 2002
    ....
  23. ncbi request reprint Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Campus Charite Mitte, Schumannstr 20 21, 10098, Berlin, Germany
    Eur J Clin Pharmacol 60:617-22. 2004
    ..Hypericin and pseudohypericin pharmacokinetics were only marginally influenced by comedication with the enzyme inhibitors and inducers cimetidine and carbamazepine...
  24. ncbi request reprint Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacokinet 44:1209-25. 2005
    ....
  25. doi request reprint Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite University Medicine, Berlin, Germany
    J Clin Psychopharmacol 28:78-83. 2008
    ..Therefore, tramadol may frequently cause adverse effects in southern European and Northern African populations with a high proportion of UMs...
  26. ncbi request reprint Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Berlin, Germany
    Pharmacogenetics 12:571-80. 2002
    ..The CYP2D6 polymorphism had a major impact on E-doxepin pharmacokinetics and CYP2D6 PMs might be at an elevated risk for adverse drug effects when treated with common recommended doses...
  27. ncbi request reprint Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 79:72-89. 2006
    ....
  28. ncbi request reprint Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Schumannstr 20 21, 10098 Berlin, Germany
    J Pharm Biomed Anal 31:551-5. 2003
    ..Sample preparation time and analysis time are both short and allow rapid analysis of large sample sets...
  29. ncbi request reprint Implications of pharmacogenetics for individualizing drug treatment and for study design
    Christian Meisel
    Institute of Clinical Pharmacology, Berlin Center for Genome Based Bioinformatics, University Hospital Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    J Mol Med (Berl) 81:154-67. 2003
    ....
  30. ncbi request reprint Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin
    Pharmacogenetics 13:721-8. 2003
    ..However, the effect of CYP2D6 genotype on steady state kinetics and on bioavailability has not been studied so far. In addition, we were interested in trimipramine pharmacokinetics in genetically defined ultra rapid metabolizers...
  31. doi request reprint Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 144:119-24. 2009
    ..However, to make codeine therapy safe, extremely high morphine formation has to be predicted as well, which has to be obtained at the effort of combining genotyping with phenotyping...
  32. ncbi request reprint Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection
    Elke Störmer
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Schumannstrasse 20 21, 10098, Berlin, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 783:207-12. 2003
    ..9 to 14.2%. The achieved limits of quantitation (LOQ) of 10 ng/ml for each analyte allowed the determination of the pharmacokinetic parameters of the analytes after administration of 100 mg celecoxib...
  33. ncbi request reprint Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology and the Department of Endocrinology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 71:286-96. 2002
    ..We explored the impact of these polymorphisms on glyburide pharmacokinetics and the effects on insulin and glucose concentrations...
  34. ncbi request reprint Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCR
    Isabella Nowakowski-Gashaw
    Institute of Clinical Pharmacology, Charite University Medical Center, Humboldt University of Berlin, 10098 Berlin, Germany
    Clin Chem 48:366-70. 2002
  35. ncbi request reprint Simulation of complex pharmacokinetic models in Microsoft Excel
    Ingolf Meineke
    Department of Clinical Pharmacology, University of Gottingen, 37075, Gottingen, Germany
    Comput Methods Programs Biomed 88:239-45. 2007
    ..While the layout of the program is admittedly geared to the needs of pharmacokineticists, it can be used in any field where sets of differential equations are involved. The software package is available upon request...
  36. doi request reprint Bioinformatic and functional analysis of TGFBR1 polymorphisms
    Markus A Schirmer
    Department of Clinical Pharmacology, University Medicine Gottingen, Georg August University, Gottingen, Germany
    Pharmacogenet Genomics 19:249-59. 2009
    ..We used bioinformatics, gene expression, and cell biological assays to evaluate the functionality of frequent inherited germline polymorphisms in the TGFB receptor 1 (TGFBR1)...
  37. ncbi request reprint Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection
    Ingolf Meineke
    Department of Clinical Pharmacology, University of Goettingen, Goettingen, Germany
    Ther Drug Monit 26:277-83. 2004
    ..Median drug levels after a 15-mg dose were 37 ng/mL mirtazapine and 20 ng/mL desmethylmirtazapine. When a 60-mg dose was administered, median concentrations of 83 ng/mL mirtazapine and 65 ng/mL desmethylmirtazapine were found...
  38. ncbi request reprint AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping
    Tanja Heller
    Department of Clinical Chemistry, Georg August University Gottingen, Robert Koch Str 40, 37099 Gottingen, Germany
    Ther Drug Monit 28:673-7. 2006
    ..It therefore represents a very efficient and fast method, offering new perspectives for the application of pharmacogenetics in clinical medicine...
  39. ncbi request reprint Therapeutic drug monitoring of mirtazapine, desmethylmirtazapine, 8-hydroxymirtazapine, and mirtazapine-N-oxide by enantioselective HPLC with fluorescence detection
    Ingolf Meineke
    Department of Clinical Pharmacology University of Goettingen, Goettingen, Germany
    Ther Drug Monit 28:760-5. 2006
    ..Because the enantiomers of mirtazapine and desmethyl mirtazapine have different pharmacological properties, the method is believed to be helpful in understanding the concentration-effect relationships in the former...
  40. ncbi request reprint Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan
    Annett Kühne
    Department of Clinical Pharmacology, Georg August University Gottingen, Gottingen, Germany
    Pharmacogenet Genomics 17:505-17. 2007
    ..As melphalan is a phenylalanine derivative, the pharmacokinetic variability may be determined by genetic polymorphisms in the L-type amino acid transporters LAT1 (SLC7A5) and LAT2 (SLC7A8)...
  41. ncbi request reprint Torasemide transport by organic anion transporters contributes to hyperuricemia
    Yohannes Hagos
    Abteilung Vegetative Physiologie und Pathophysiologie, Georg August Universitat, Gottingen, Germany
    J Am Soc Nephrol 18:3101-9. 2007
  42. doi request reprint A putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a potential biomarker for radiosensitivity
    Markus A Schirmer
    Department of Clinical Pharmacology, University Medical Center Gottingen, Gottingen, Germany
    Int J Radiat Oncol Biol Phys 79:866-74. 2011
    ..To determine whether genetic variability in TGFB1 is related to circulating transforming growth factor-β1 (TGF-β1) plasma concentrations after radiotherapy and to radiosensitivity of lymphoid cells...
  43. ncbi request reprint Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Berlin, Germany
    Biomed Chromatogr 16:187-90. 2002
    ..3 to 13.7%, respectively. The sensitivity and precision were sufficient for determination of plasma concentrations after therapeutic administration of both drugs and the method can be used for the estimation of pharmacokinetic parameters...
  44. ncbi request reprint Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter
    Rolf Kaiser
    Institute of Clinical Pharmacology, Universitatsklinikum Charite, Humboldt Universitat zu Berlin, Berlin, Germany
    Am J Med Genet 114:323-8. 2002
    ..This was also observed for the combined analysis of both polymorphisms. In conclusion, we found no association between the different genotypes of the 44-bp polymorphism and the 17-bp VNTR and maximum rate of 5-HT uptake into platelets...
  45. ncbi request reprint A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, D 10098 Berlin, Germany
    Cancer Epidemiol Biomarkers Prev 12:68-70. 2003
    ..60-8.51; P = 0.002). In general, 81CC occurred more frequently in advanced types of bladder cancer. We conclude that individuals harboring the homozygous 81C-genotype of the H-ras proto-oncogene are at an increased risk of bladder cancer...
  46. ncbi request reprint Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction
    Klaus Abraham
    Department of Pediatric Pneumology and Immunology, Institute of Clinical Pharmacology, Charite, Humboldt University Berlin, Augustenburger Platz 1, 13 153 Berlin, Germany
    Clin Pharmacol Ther 72:163-74. 2002
    ..We compared the performance of several modifications of the caffeine test for measurement of CYP1A2 activity in subjects with exceptionally high, low, or absent enzyme induction...
  47. ncbi request reprint Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Germany
    Clin Pharmacol Ther 72:584-94. 2002
    ..According to earlier data, homozygous TT of the exon 26 complementary deoxyribonucleic acid (cDNA) 3435C>T polymorphism was associated with low P-gp expression in the human intestine...